No credit card. No commitment.
5000+ G2 reviews
Renalytix
Research
Public company
Founded in 2018
New York, New YorkRenalytix
ResearchPublic companyFounded in 2018New York, New York
EmployeesRenalytix's financial review
Renalytix's Revenue (Yearly)
2.8M
Employees
57
Total Funding
148.4M
Last Funding Round
15.1M
nasdaq
RNLX
Market cap
32.8M
Renalytix information
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the founder and global leader in the new field of bioprognosis™ for kidney health. We've engineered a proprietary solution that successfully enables early-stage, progression risk assessment when it counts the most. Renalytix. Right here, until kidney disease isn't.™
Renalytix industries
Research
Medical specialities
Health care
Biotechnology research
Renalytix's financial review
Renalytix's Revenue (Yearly)
2.8M
Employees
57
Total Funding
148.4M
Last Funding Round
15.1M
nasdaq
RNLX
Market cap
32.8M
Employee Metrics
Technologies
Customer Relationship Management
Email Providers
Other
Hosting
Captcha
Fonts
Notable Alumni
Employees
Global Head, Marketing & Brand
Senior Manager, Strategic Finance
Account Executive
Prospect on LinkedIn
Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download Extension
Why our clients choose Apollo
“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Erik Straub
Head of Product, Kickfurther
“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
Michael Transon
CEO, Victorious
